Design Therapeutics (DSGN) Income towards Parent Company (2020 - 2026)

Design Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$23.4 million in Q2 2026.

• Income towards Parent Company for Q2 2026 came in at -$23.4 million, down 7.16% year-over-year; the trailing twelve-month figure through Jun 2026 was -$81.8 million (down 11.06% YoY), and the FY2025 annual result was -$53.8 billion, down 173.08% from the prior year.
• Income towards Parent Company slipped to -$23.4 million in Q2 2026, from -$21.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$13.3 million in Q1 2024 and troughed at -$10.6 billion in Q4 2022.
• A 5-year average of -$606.8 million and a median of -$21.2 million in 2022 frame the typical range for Income towards Parent Company.
• The widest annual swing landed in 2022, when Income towards Parent Company slumped 92733.1%; it then soared 99.54% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at -$10.6 billion in 2022, then soared by 99.54% to -$48.3 million in 2023, then jumped by 66.28% to -$16.3 million in 2024, then fell by 11.63% to -$18.2 million in 2025, then dropped by 28.61% to -$23.4 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$23.4 million in Q2 2026, -$21.0 million in Q1 2026, and -$18.2 million in Q4 2025.